The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Congrats on a good quarter. Maybe I can ask about the guidance. And maybe, Maggie, walk me through just the thought process here on the beat.
Even if you'd back out the $5 million from China, it was still a $4 million beat in the quarter, reiterating guidance. So just walk me through the puts
and takes there and why you decided to hold guidance?
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Okay. So just chalk it up to conservatism earlier in the year, and nothing that we should read into beyond that.
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Great. And maybe if I turn to the Neuro business, the growth rates are impacted. We don't know how much of the $5 million move from one to the
other. So part a, wondering if you could give us adjusted growth rates, excluding the China contract. And b, this is a market -- the growth rates
have slowed down, there's a lot of competitors. Others are talking about increased competition in neuro. So maybe you could just give us a quick
state of the union, what you're seeing in terms of underlying growth, geographic growth, if it's different. And any impacts from competitors.
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Do you have the global numbers that you're able to share, since we don't get the segment geographic breakdown?
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Excluding that -- the mix shift in revenue?
|
